Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Targovax ASA ( (GB:0RIS) ) has issued an announcement.
Circio Holding ASA, a biotech company focused on circular RNA technologies for next-generation gene and cell therapies, has developed its proprietary circVec platform to improve durability and expression of therapeutic genes across genetic medicine, cell therapy and chronic disease indications. The platform is advanced by its wholly owned subsidiary Circio AB in Stockholm, which aims to position circVec as a potential new standard in gene expression technology.
The company has been selected to deliver an oral presentation at the American Society of Gene and Cell Therapy annual meeting in Boston in May 2026, with a second abstract accepted as a poster. The ASGCT slot gives Circio a high-visibility forum to showcase the performance of its circVec platform to a global audience of industry and academic stakeholders, potentially strengthening its scientific profile and supporting future R&D collaborations and business development efforts.
More about Targovax ASA
Circio Holding ASA is a biotechnology company specializing in novel circular RNA expression technology for gene and cell therapy applications. Its proprietary circVec platform is a modular genetic construct designed to produce multifunctional circular RNA in target cells, offering markedly extended RNA half-life and significantly enhanced protein expression compared with conventional mRNA-based viral and non-viral vector systems.
Average Trading Volume: 7,287,217
Current Market Cap: NOK1.03B
For a thorough assessment of 0RIS stock, go to TipRanks’ Stock Analysis page.